The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Respiratory Distress Syndrome Market Research Report 2024
Synopsis
Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
The global Respiratory Distress Syndrome market was valued at US$ 377.7 million in 2023 and is anticipated to reach US$ 551.9 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.
North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.
This report aims to provide a comprehensive presentation of the global market for Respiratory Distress Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Distress Syndrome.
Report Scope
The Respiratory Distress Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Distress Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Distress Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Chiesi Farmaceutici
CR-Double Crane
ONY Biotech
AbbVie
Yuhan Corporation
JW Pharmaceuticals
Noargen
Segment by Type
Poractant Alfa
Beractant
Calfactant
Others
Segment by Application
Very Preterm Infants
Moderate to Late Preterm Infants
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Distress Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
The global Respiratory Distress Syndrome market was valued at US$ 377.7 million in 2023 and is anticipated to reach US$ 551.9 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.
North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.
This report aims to provide a comprehensive presentation of the global market for Respiratory Distress Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Distress Syndrome.
Report Scope
The Respiratory Distress Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Distress Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Distress Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Chiesi Farmaceutici
CR-Double Crane
ONY Biotech
AbbVie
Yuhan Corporation
JW Pharmaceuticals
Noargen
Segment by Type
Poractant Alfa
Beractant
Calfactant
Others
Segment by Application
Very Preterm Infants
Moderate to Late Preterm Infants
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Distress Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Distress Syndrome Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Poractant Alfa
1.2.3 Beractant
1.2.4 Calfactant
1.2.5 Others
1.3 Market by Application
1.3.1 Global Respiratory Distress Syndrome Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Very Preterm Infants
1.3.3 Moderate to Late Preterm Infants
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Distress Syndrome Market Perspective (2019-2030)
2.2 Respiratory Distress Syndrome Growth Trends by Region
2.2.1 Global Respiratory Distress Syndrome Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Respiratory Distress Syndrome Historic Market Size by Region (2019-2024)
2.2.3 Respiratory Distress Syndrome Forecasted Market Size by Region (2025-2030)
2.3 Respiratory Distress Syndrome Market Dynamics
2.3.1 Respiratory Distress Syndrome Industry Trends
2.3.2 Respiratory Distress Syndrome Market Drivers
2.3.3 Respiratory Distress Syndrome Market Challenges
2.3.4 Respiratory Distress Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Distress Syndrome Players by Revenue
3.1.1 Global Top Respiratory Distress Syndrome Players by Revenue (2019-2024)
3.1.2 Global Respiratory Distress Syndrome Revenue Market Share by Players (2019-2024)
3.2 Global Respiratory Distress Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Respiratory Distress Syndrome Revenue
3.4 Global Respiratory Distress Syndrome Market Concentration Ratio
3.4.1 Global Respiratory Distress Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Distress Syndrome Revenue in 2023
3.5 Respiratory Distress Syndrome Key Players Head office and Area Served
3.6 Key Players Respiratory Distress Syndrome Product Solution and Service
3.7 Date of Enter into Respiratory Distress Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Distress Syndrome Breakdown Data by Type
4.1 Global Respiratory Distress Syndrome Historic Market Size by Type (2019-2024)
4.2 Global Respiratory Distress Syndrome Forecasted Market Size by Type (2025-2030)
5 Respiratory Distress Syndrome Breakdown Data by Application
5.1 Global Respiratory Distress Syndrome Historic Market Size by Application (2019-2024)
5.2 Global Respiratory Distress Syndrome Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Respiratory Distress Syndrome Market Size (2019-2030)
6.2 North America Respiratory Distress Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Respiratory Distress Syndrome Market Size by Country (2019-2024)
6.4 North America Respiratory Distress Syndrome Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Distress Syndrome Market Size (2019-2030)
7.2 Europe Respiratory Distress Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Respiratory Distress Syndrome Market Size by Country (2019-2024)
7.4 Europe Respiratory Distress Syndrome Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Distress Syndrome Market Size (2019-2030)
8.2 Asia-Pacific Respiratory Distress Syndrome Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Respiratory Distress Syndrome Market Size by Region (2019-2024)
8.4 Asia-Pacific Respiratory Distress Syndrome Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Distress Syndrome Market Size (2019-2030)
9.2 Latin America Respiratory Distress Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Respiratory Distress Syndrome Market Size by Country (2019-2024)
9.4 Latin America Respiratory Distress Syndrome Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Distress Syndrome Market Size (2019-2030)
10.2 Middle East & Africa Respiratory Distress Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Respiratory Distress Syndrome Market Size by Country (2019-2024)
10.4 Middle East & Africa Respiratory Distress Syndrome Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Chiesi Farmaceutici
11.1.1 Chiesi Farmaceutici Company Detail
11.1.2 Chiesi Farmaceutici Business Overview
11.1.3 Chiesi Farmaceutici Respiratory Distress Syndrome Introduction
11.1.4 Chiesi Farmaceutici Revenue in Respiratory Distress Syndrome Business (2019-2024)
11.1.5 Chiesi Farmaceutici Recent Development
11.2 CR-Double Crane
11.2.1 CR-Double Crane Company Detail
11.2.2 CR-Double Crane Business Overview
11.2.3 CR-Double Crane Respiratory Distress Syndrome Introduction
11.2.4 CR-Double Crane Revenue in Respiratory Distress Syndrome Business (2019-2024)
11.2.5 CR-Double Crane Recent Development
11.3 ONY Biotech
11.3.1 ONY Biotech Company Detail
11.3.2 ONY Biotech Business Overview
11.3.3 ONY Biotech Respiratory Distress Syndrome Introduction
11.3.4 ONY Biotech Revenue in Respiratory Distress Syndrome Business (2019-2024)
11.3.5 ONY Biotech Recent Development
11.4 AbbVie
11.4.1 AbbVie Company Detail
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Respiratory Distress Syndrome Introduction
11.4.4 AbbVie Revenue in Respiratory Distress Syndrome Business (2019-2024)
11.4.5 AbbVie Recent Development
11.5 Yuhan Corporation
11.5.1 Yuhan Corporation Company Detail
11.5.2 Yuhan Corporation Business Overview
11.5.3 Yuhan Corporation Respiratory Distress Syndrome Introduction
11.5.4 Yuhan Corporation Revenue in Respiratory Distress Syndrome Business (2019-2024)
11.5.5 Yuhan Corporation Recent Development
11.6 JW Pharmaceuticals
11.6.1 JW Pharmaceuticals Company Detail
11.6.2 JW Pharmaceuticals Business Overview
11.6.3 JW Pharmaceuticals Respiratory Distress Syndrome Introduction
11.6.4 JW Pharmaceuticals Revenue in Respiratory Distress Syndrome Business (2019-2024)
11.6.5 JW Pharmaceuticals Recent Development
11.7 Noargen
11.7.1 Noargen Company Detail
11.7.2 Noargen Business Overview
11.7.3 Noargen Respiratory Distress Syndrome Introduction
11.7.4 Noargen Revenue in Respiratory Distress Syndrome Business (2019-2024)
11.7.5 Noargen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
